



An entrepreneurial world
where people make the difference

Q3 Report 2025

Bo Annvik, President and CEO
Patrik Johnson, CFO

21 October 2025

Highlights third quarter 2025

- Improved demand – organic order growth of 3%.
 - 4 out of 5 business areas and more than half of the companies grew organically
 - Strong demand from customers within medical technology & pharmaceuticals
 - Good demand development within several of the larger customer segments
- Net sales decreased by 2% in total, organically -1%.
- Strong EBITA margin of 14.6%.
- Lower total working capital and continued inventory reductions.
- 10 acquisitions so far in 2025, with a total annual turnover of SEK 1.1 billion.

Net Sales


7.8

BSEK


EBITA margin

14.6%

Improved demand



Q3 Growth	TOTAL	ORGANIC	ACQUISITIONS	DIVESTMENTS	CURRENCY
	3%	3%	3%	-1%	-2%





Q3 Growth	TOTAL	ORGANIC	ACQUISITIONS	DIVESTMENTS	CURRENCY
	-2%	-1%	3%	-1%	-3%

Organic sales development Q3 – major countries


Nordics		Rest of Europe		Rest of the world	
Sweden	↗	Benelux	↗	North America	↘
Denmark	↘	UK/Ireland	↗	Asia	↗
Finland	→	Germany	→		
Norway	→	Switzerland & Austria	→		
Total Nordics	→	Total Rest of Europe	→	Total Rest of the world	↘

Strong EBITA-margin




	Q3-25 MARGIN	Q GROWTH	YTD GROWTH
1,143 MSEK	14.6%	-3%	-3%

Net Sales by Business Area



- Strongest organic development in Process, Energy & Water, and unchanged in Technology & Systems Solutions.
- Weak general business climate impacting Business Areas Infrastructure & Construction and Industrial & Engineering.
- Development in Life Science mainly explained by strong references, with significant sales of products for pharmaceutical production in Denmark last year.

EBITA margin by Business Area





- Record high Q3 gross margin.
- Organic expenses slightly higher than last year.
- EBITA margin improved in two business areas.
 - Infrastructure & Construction impacted positively by acquisitions and divestments
 - Gross margin development the main driver for Life Science.
- EBITA margins in line with last year in Industrial & Engineering, Process, Energy & Water and Technology & Systems Solutions.

Increased acquisition pace

#	Company	Country	Business area	Announced	Annual sales
1.	 ECOROLL surface matters	Germany	Industrial & Engineering	Q1	150 MSEK
2.		Ireland	Life Science	Q1	185 MSEK
3.		Sweden	Industrial & Engineering	Q2	55 MSEK
4.	 UTODAS turns your stock into profit	Netherlands	Technology & Systems Solutions	Q3	35 MSEK
5.		Italy	Life Science	Q3	85 MSEK
6.	Optimed	Poland	Life Science	Q3	35 MSEK
7.	 SCAN AUTO  DYBBROE GROUP A/S OE CENTER SCANDINAVIA	Denmark	Industrial & Engineering	Q3	185 MSEK
8.		UK	Technology & Systems Solutions	Q3	105 MSEK
9.		Sweden	Life Science	Q3	50 MSEK
10.		Netherlands	Industrial & Engineering	Q4	165 MSEK
					Total 1,050 MSEK

Successful acquisition track record




* "bridge effects" from acquisitions last 12 months from date of closing, in respective quarter

Key data summary


MSEK	2025-Q3	2024-Q3	Change	2025-YTD	2024-YTD	Change
Order Intake	7,735	7,537	3%	24,487	23,870	3%
Net Sales	7,846	7,973	-2%	24,003	24,208	-1%
Gross margin, %	35.5	34.0		35.4	34.8	
EBITA	1,143	1,182	-3%	3,352	3,468	-3%
EBITA-margin, %	14.6	14.8		14.0	14.3	
Net financial items	-99	-143	-31%	-334	-398	-16%
Tax	-201	-172	17%	-581	-566	3%
Earnings per share (before dilution), SEK	1.85	1.92	-4%	5.31	5.53	-4%
Return On Capital Employed, %	19	19		19	19	
Cash Flow from operating activities	1,016	1,019	0%	2,395	2,535	-6%
Net debt / EBITDA, times	1.4	1.6		1.4	1.6	

Cash Flow from operating activities




- Operating cash flow during the quarter amounted to SEK 1,016 million (1,019), in line with corresponding period last year.
- Lower total organic working capital and inventory than last year.
- Continued strong cash conversion.
- The working capital efficiency** was better than last year.

Earnings per share




- EPS decreased 4% in the quarter to SEK 1.85 (1.92) per share.
- 3- and 5-year rolling 4Q earnings per share CAGR, were 2% and 10%.

Strong financial position



- The interest-bearing net debt decreased since same period last year to SEK 8,100 million (8,843).
- Net debt/equity ratio was 48% (56%).
- Net debt/EBITDA was 1.4x (1.6x). Excluding earn-out liabilities 1.3x (1.4x).

Companies adapt their cost base and head count



Key takeaways

- The positive demand development continues – order intake up 3% organically.
- Slightly lower organic sales, mainly due to challenging references.
- Strong EBITA margin of 14.6%.
- Companies continue to work actively with adapting costs to their respective market situations.
- Market uncertainty remains for the upcoming quarter – slightly larger order book and higher acquisition pace provide some comfort about the earnings trend.
- 10 companies acquired so far in 2025 – good pipeline!
- Strong platform for long-term sustainable, profitable growth!

Capital Markets Day 2025

4 November 11:30-17:00
Operaterrassen
Stockholm

www.indutrade.com

Thank you!

Q&A



Financial calendar & contact details

29 JANUARY 2026

Q4 Report

1 APRIL 2026

AGM

24 APRIL 2026

Q1 Report

16 JULY 2026


Q2 Report

23 OCTOBER 2026

Q3 Report

Contact: ir@indutrade.com

+46 8 703 03 00





Trusted by
entrepreneurs